Skip to main content

Table 1 Baseline characteristics of 64 patients with Child-Pugh class A and 56 patients matched by propensity score

From: Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis

  Entire cohort PS-matched cohort
  Sorafenib RT Pvalue Sorafenib RT Pvalue
Covariates n = 36 n = 28   n = 28 n = 28  
Age (years) 70 (62–78) 67 (61–71) 0.069 70 (61–78) 67 (61–70) 0.04
Sex (male/female) 31/5 19/9 0.127 23/5 19/9 0.355
HCV 19/17 17/11 0.615 16/12 17/11 1.0
*Main/first branch 7/29 9/19 0.262 7/24 9/19 0.205
Metastases (present/absent) 7/29 2/26 0.278 6/22 2/26 0.252
Previous Treatments (present/absent) 26/10 20/8 1.0 18/10 20/8 0.775
TACE/TAI 21 20   15 20  
RFA 3 0   2 0  
RT 2 0   1 0  
AFP (ng/dL) 1047 (44–5919) 43 (10–1096) 0.005 680 (37–3708) 43 (10–1096) 0.144
DCP (mAU/mL) 2915 (111–19706) 224 (33–2880) 0.013 2151 (58–10775) 224 (33–2880) 0.488
  1. Data are presented as medians (range).
  2. Abbreviations: TACE transarterial chemoembolization, TAI transarterial infusion chemotherapy, RFA radiofrequency ablation, RT radiotherapy, HCV hepatitis C virus, AFP α-fetoprotein, DCP des-γ-carboxy prothrombin, AST aspartate aminotransferase, ALT alanine aminotransferase, PS propensity score.
  3. *Portal tumor invasion to the main trunk or first branch.